Section
The LUMINARA trial evaluates AZD5462, an oral relaxin receptor agonist, demonstrating safety and promising effects on cardiac remodeling and vascular resistance in chronic heart failure, warranting further large-scale investigation.
GLP-1 receptor agonists reduce mortality and cardiovascular events more effectively than SGLT2 inhibitors in serious mental illness (SMI), with early benefits and consistent effects across bipolar disorder, major depression, and schizophren
A randomized clinical trial demonstrates that routine cardiovascular specialist referral for prostate cancer patients improves cholesterol control but does not reduce major cardiovascular events over nearly 6 years.
This study characterizes abnormal lymphatic reflux patterns in primary chylopericardium using direct lymphangiography and demonstrates that guided cervical thoracic duct exploration yields a 66% long-term success rate, with specific reflux
This study introduces a causal endotype-based classification of myocardial infarction, revealing distinct underlying mechanisms and clinical outcomes beyond the traditional type 1/type 2 framework, potentially improving MI diagnosis and man
This article explores the latest evidence on antithrombotic therapy after PCI in patients with atrial fibrillation, highlighting the balance between bleeding risk and prevention of ischemic events.
Healthcare professionals face significant gaps in cardiovascular prevention despite their critical role in care. The ESC Congress 2025 revealed prevalent modifiable risks, underuse of therapies, and subclinical atherosclerosis, underscoring
The HELIOS-B trial showed vutrisiran improves survival and cardiac outcomes in transthyretin amyloidosis with cardiomyopathy, with consistent benefits regardless of baseline tafamidis use, supporting further evaluation of combination therap
The NOTION-4 trial demonstrates that 3 months of DOAC therapy post-TAVR reduces early HALT incidence compared to SAPT, but benefits diminish after discontinuation, highlighting nuanced balance between thrombosis prevention and bleeding risk
A nurse-led, mobile health-supported collaborative care intervention significantly increased days alive and out of hospital and reduced mortality among Indian patients with heart failure with reduced ejection fraction over 2 years.
Elevated lipoprotein(a) confers a consistent relative risk increase for atherosclerotic cardiovascular disease across all adult ages, with absolute risks rising substantially in older adults.
This study shows that the choice of cannulation site—femoral versus axillary—does not independently affect early mortality or neurological complications after acute type A aortic dissection repair; instead, timely systemic reperfusion and c
The RNF213 p.R4810K variant independently increases risk and severity of extracranial carotid artery disease, distinct from its known association with intracranial atherosclerosis, highlighting new insights into vascular disease genetics an
A novel deep learning algorithm accurately detects moderate or greater aortic stenosis using AI-guided focused cardiac ultrasound acquired by novice operators, presenting a scalable solution to expand screening accessibility.
A novel machine learning-based model demonstrates improved risk prediction in transthyretin amyloid cardiomyopathy, surpassing traditional staging systems and supporting personalized patient management.
The PROFID study reveals a declining mortality benefit from primary prevention implantable cardioverter-defibrillators in post-myocardial infarction patients with reduced ejection fraction over recent decades, highlighting changing clinical
EUROASPIRE VI exposes wide gaps between ESC prevention and cardiac rehabilitation recommendations and everyday care across Europe — especially in high-risk regions. This article distills core guideline recommendations, what’s new, and
Evolocumab significantly reduces first and subsequent major adverse cardiovascular events in high-risk patients without prior myocardial infarction or stroke, affirming the benefit of intensive LDL-C lowering for cumulative cardiovascular r
Lower ventricular chamber stiffness predicts adverse outcomes in Fontan patients, revealing a high-compliance, eccentric remodeling phenotype distinct from traditional stiffening hypotheses.
Long-term intensive BP control led by trained nonphysician community providers significantly lowers cardiovascular risk over 7 years, with benefits persisting 3 years post-intervention in rural China.
